Rare condition

Uterine arteriovenous malformation

ORPHA:693815 ↗Malformation syndrome

0

studies recruiting now

as of 7 Sept 2026

3

studies registered in total

as of 7 Sept 2026

0

countries with a recruiting site

as of 7 Sept 2026

None

recruiting study posted to date

among recruiting studies

Recruiting trials

No recruiting trial found right now.

3 studies are registered for Uterine arteriovenous malformation, but none was recruiting as of 7 Sept 2026. Here is what is still worth doing.

Keep watching

Get an email when a new Uterine arteriovenous malformation study opens.

One email a day at most. Unsubscribe with one click.

Used only for these alerts. Privacy.

Support

Patient organisations

We do not yet list a dedicated organisation for this condition. The directories below are the best route.

About Uterine arteriovenous malformation

RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations.

Treatments being studied

1 approved treatment and 13 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.

Approved: Ranibizumab (Byooviz)
Phase 3Bevacizumab (Abevmy)
Phase 3Propranolol
Phase 3Tranexamic Acid (Cyklo-f heavy period relief)
Phase 3Sodium Chloride (Aqsia (balanced salt soln))
Phase 3Mupirocin (Bactroban)
Phase 2Pazopanib (Votrient)
Phase 2Tamoxifen
Phase 2Doxycycline Hyclate (Acticlate)

+ 5 more in development

Related conditions

Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).